Nature Communications publication highlights new applications for highly-sensitive SHG technology SOUTH SAN FRANCISCO, Calif. – Nov. 20, 2017 – Biodesy, Inc., a leader in next-generation technologies measuring structure and structural changes at the molecular level, today announced that its Delta ® System was used to discover a novel mechanism involved in the earliest steps of viral infection. The collaborative study

Biodesy Appoints Dominique Bridon as Chief Executive Officer

Biodesy’s article, “Protein Conformational Changes Are Detected and Resolved Site Specifically by Second-Harmonic Generation” published in Biophysical Journal was announced as one of the most popular articles in the journal in 2015 at the Biophysical Society meeting.

Biodesy was featured in “The Shape of Proteins to Come,” an article recently published in The Translational Scientist.

2016 Prism Award recognizes product innovation and potential to tackle grand challenges of our time

Company signs 20th pharmaceutical service contract; funds to be used to commercialize the Biodesy™ Delta System

Biodesy™ Delta System and performance data to be presented at upcoming Society for Laboratory Automation & Screening Meeting

Biodesy, Inc. announced it entered into a research collaboration agreement with Amgen Inc. to support Amgen’s neuroscience drug discovery programs.

Frost & Sullivan proudly recognizes Biodesy as the recipient of the 2014 Technology Innovation Leadership Award for Protein Analysis

Series A investors include 5AM Ventures, Pfizer Venture Investments and Roche Venture Fund

Biodesy announced it has received a supplement to its Phase II Small Business Innovation Research (SBIR) Award from the National Science Foundation (NSF)